EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
57.90
-2.99 (-4.91%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close60.89
Open59.88
Bid56.50 x 1000
Ask59.50 x 1000
Day's Range56.72 - 60.02
52 Week Range35.25 - 123.99
Volume1,848,542
Avg. Volume2,699,745
Market Cap8.567B
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.64
Earnings DateApr 27, 2020 - May 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est115.29
  • Epic, Exact Sciences among Wisconsin tech firms responding to COVID-19
    American City Business Journals

    Epic, Exact Sciences among Wisconsin tech firms responding to COVID-19

    Madison-based biotechnology company Promega Corp. is working on producing reagent materials needed in testing for COVID-19.

  • Exact Sciences Takes Action during COVID-19 Pandemic
    PR Newswire

    Exact Sciences Takes Action during COVID-19 Pandemic

    Exact Sciences Corp. (NASDAQ: EXAS) today provided an update on the actions it is taking to support patients, employees, and public health initiatives in response to the coronavirus (COVID-19) pandemic.

  • Exact Sciences (EXAS) Gains But Lags Market: What You Should Know
    Zacks

    Exact Sciences (EXAS) Gains But Lags Market: What You Should Know

    In the latest trading session, Exact Sciences (EXAS) closed at $42.47, marking a +0.14% move from the previous day.

  • Hedge Funds Have Never Been This Bullish On EXACT Sciences Corporation (EXAS)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On EXACT Sciences Corporation (EXAS)

    Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • Exact Sciences (EXAS) Down 39.7% Since Last Earnings Report: Can It Rebound?
    Zacks

    Exact Sciences (EXAS) Down 39.7% Since Last Earnings Report: Can It Rebound?

    Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
    Benzinga

    The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) * Acceleron Pharma Inc (NASDAQ: XLRN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Fate Therapeutics Inc (NASDAQ: FATE) (reacted to its fourth-quarter results) * Forty Seven Inc (NASDAQ: FTSV) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO)( announced an accelerated timeline for COVID-19 vaccine development) * Repro-Med Systems, Inc. (NASDAQ: KRMD) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 3) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * Akorn, Inc. (NASDAQ: AKRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) * Midatech Pharma PLC-ADR (NASDAQ: MTP)(began trading on a reverse split adjusted basis) * Mylan NV (NASDAQ: MYL) * Neuronetics Inc (NASDAQ: STIM)(announced its fourth-quarter results) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * SurModics, Inc. (NASDAQ: SRDX) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TransMedics Group Inc (NASDAQ: TMDX)(reported its fourth-quarter results) * VIVUS, Inc. (NASDAQ: VVUS) * Xeris Pharmaceuticals Inc (NASDAQ: XERS)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA DatesStocks In Focus Takeda To Develop COVID-19 Treatments Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin to treat high-risk individuals with the viral infection. Hyperimmune globulins are plasma-derived therapies that had previously proven its efficacy in treating severe acute viral respiratory infections.The company added it is also studying its currently marketed and pipeline products to see whether they are effective treatments for infected patients.Separately, the company said it has completed its previously announced sale of portfolio of select products to STADA for $660 million.In pre-market trading Wednesday, Takeda shares were adding 3.94% to $18.20.Vir, Alnylam Expands Collaboration To Develop siRNA Therapies For COVID-19 Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced an expansion to their existing collaboration to include the development and commercialization of RNAi therapeutics against COVID-19. The agreement provides for Vir using Alnylam's recent advances in lung delivery of novel conjugates of siRNA along with its infectious disease expertise to develop one or some siRNAs to treat COVID-19 and other coronaviruses as well.In premarket trading Wednesday, Vir share were rallying 14.72% to $47 and Alnylam was edging up 0.41% to $111.88.Mallinckrodt Reports Positive Outcome Analysis of Acthar Gel In Immune-mediated Diseases Mallinckrodt PLC (NYSE: MNK) announced findings from a retrospective medical record analysis, which assessed practice patterns and outcomes of Acthar Gel in the treatment of immune-mediated diseases rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis, which showed across all the three patient populations, symptoms improved with Acthar Gel.In premarket trading Wednesday, the shares were advancing 7.99% $3.38.Acadia's Rett Syndrome Investigational Drug Gets Rare Pediatric Designation ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharma said the FDA has granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.Upon approval of a product with the designation, the sponsor is eligible to receive a Priority Review Voucher, which can be used to obtain FDA approval of an NDA for another product in an expedited period of six months.Acadia shares were up 2.41% to $42.99 in after-hours trading.Morphosys' Licensing Agreement With Incyte For Lymphoma Drug Gets Antitrust Clearance Morphosys Ag (NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) said their joint collaboration and license agreement for further development and global commercialization of Morphosys' investigational compound tafasitamab has received antitrust clearance and becomes effective Tuesday.The regulatory milestone triggers a $750 million upfront payment by Incyte to Morphosys, and also Incyte's equity investment of $150 million into MorphoSys within the defined timelines.The PDUFA date for the BLA for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma is Aug. 30.Ultragenyx CFO To Step Down Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) said Shalini Sharp will step down as CFO and EVP, effective Sept. 2. The company said it will initiate a search for a successor.Exact Sciences Buys Two Cancer Diagnostics Companies Exact Sciences said it has completed its acquisition of Paradigm Diagnostics and Viomics, two privately held companies, which provide a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery.View more earnings on TAKThe company expects the acquisition to extend its lab testing and research and development capabilities.J&J Makes Regulatory Submission For Approval of Multiple Sclerosis Drug In Europe Johnson & Johnson's (NYSE: JNJ) Janssen unit announced it submitted a Marketing Authorization Application to EMA, seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis.Earnings DURECT Corporation (NASDAQ: DRRX) reported fourth-quarter net revenues of $10.69 million compared to $3.63 million last year. The net loss per share narrowed from 5 cents to 2 cents, in line with the consensus estimate.The stock jumped 12.21% to $1.93 in after-hours trading.Menlo Therapeutics Inc's (NASDAQ: MNLO), which has agreed to be bought by Foamix Pharmaceuticals Ltd (NASDAQ: FOMX), reported a wider loss of 89 cents per share compared to the year-ago loss of 76 cents per share and the consensus loss estimate of 83 cents per share.Updating on the pending merger, Menlo said it expects it to close March 9.The stock jumped 23.64% to $3.40 in after-hours trading.Voyager Therapeutics Inc (NASDAQ: VYGR) reported fourth quarter revenues of $32.67 million compared to $2.01 million a year ago. The net loss per share narrowed from 77 cents to 34 cents. Analysts had estimated a loss of 81 cents per share. The company said it expects its cash reserves as well as receivables to be sufficient to meet its projected operating expenses and capex into mid-2022.The stock gained 6.22% to $12.30 in after-hours trading.Vivus reported fourth-quarter total revenues of $17.25 million and a loss of 61 cents per share, narrower than the 68 cents per share loss expected by analysts.The stock rose 8.98% to $1.82 in after-hours trading.Offerings Zogenix, Inc. (NASDAQ: ZGNX) said it has priced its underwritten public offering of 8.52 million shares at $23.50 per share. The company expects to raise gross proceeds of $200.2 million from the offering. The offering is expected to close on or about March 6.The company said it expects to use the net proceeds for the potential commercialization of Fintepla for the treatment of Dravet syndrome, among other things.The stock fell 3.69% to $24 in after-hours trading.On The Radar Earnings * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (before the market open) * Recro Pharma Inc (NASDAQ: REPH) (before the market open) * PPD Inc (NASDAQ: PPD) (before the market open) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (after the close) * Orthopediatrics Corp (NASDAQ: KIDS) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close)See more from Benzinga * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
    Zacks

    Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

    The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

  • Benzinga

    The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...

  • Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2028
    PR Newswire

    Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2028

    Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2028 (the "Notes") and upsized the offering from $850 million to $1.0 billion aggregate principal amount. The Company has granted the underwriter a 30-day option to purchase up to an additional $150.0 million aggregate principal amount of the Notes solely to cover over-allotments, if any.

  • Exact Sciences Announces Offering of $850 Million Convertible Senior Notes Due 2028
    PR Newswire

    Exact Sciences Announces Offering of $850 Million Convertible Senior Notes Due 2028

    Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $850 million aggregate principal amount of convertible senior notes due 2028 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $127.5 million aggregate principal amount of the Notes. The Company intends to use the net proceeds of this offering for general corporate purposes, which may include the repayment or repurchase of debt, working capital and possible acquisitions. The Notes will be convertible into cash, shares of the Company's common stock (and, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election.

  • Bull of the Day: Guardant Health (GH)
    Zacks

    Bull of the Day: Guardant Health (GH)

    Bull of the Day: Guardant Health (GH)

  • Thomson Reuters StreetEvents

    Edited Transcript of EXAS earnings conference call or presentation 11-Feb-20 10:00pm GMT

    Q4 2019 Exact Sciences Corp Earnings Call

  • Exact Sciences to acquire more biotech companies; plans to launch liver cancer test in 2020
    American City Business Journals

    Exact Sciences to acquire more biotech companies; plans to launch liver cancer test in 2020

    Madison-based biotechnology company Exact Sciences Corp. is planning to grab a larger share of the $20 billion cancer diagnostic market with two more acquisitions. In an earnings call with analysts on Monday, CEO Kevin Conroy said his company, which makes the Cologuard take-home colon cancer screening test, had signed agreements to acquire Phoenix-area med tech companies Paradigm Diagnostics Inc. and Viomics. An estimated closing date for the acquisitions, or the financial details of the deals, were not disclosed.

  • Benzinga

    The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...

  • Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y
    Zacks

    Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

    Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.

  • Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

    Exact Sciences (EXAS) delivered earnings and revenue surprises of 0.00% and 0.40%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Exact Sciences beats income, revenue projections in 4Q earnings report
    American City Business Journals

    Exact Sciences beats income, revenue projections in 4Q earnings report

    The company's fourth-quarter revenue, which is a 60% increase from the same quarter in 2018, is the combination of both Exact Sciences and Genomic Health, the California company Exact Sciences acquired last year in a $2.8 billion deal.

  • Exact Sciences Announces Fourth-Quarter 2019 Results
    PR Newswire

    Exact Sciences Announces Fourth-Quarter 2019 Results

    Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $295.6 million for the fourth quarter ended Dec. 31, 2019 and $876.3 million for the full year ended Dec. 31, 2019, including Precision Oncology revenue of $66.2 million for the period Nov. 8, 2019 through Dec. 31, 2019, following the close of the Genomic Health combination.

  • Benzinga

    The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...

  • Should Growth Investors Buy this Cancer Screening Biotech Stock?
    Zacks

    Should Growth Investors Buy this Cancer Screening Biotech Stock?

    Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

  • Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks

    Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
    Zacks

    What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

    Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.